BRCA1 and neoplasm: Analyses of effects of germline BRCA1/2 mutation and/or presence of tumor-based HRD mutational signatures are complex showing a lack of prediction of carboplatin benefit, likely confounded by the frequency of epigenetic and genetic causes of HRD operating in a treatment-naïve context (8) as discussed in our previous manuscript (1).